Belatacept denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belatacept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Imposes Quantity Limits on Belatacept

Belatacept is administered as an intravenous infusion on a schedule defined by the FDA-approved prescribing label. UnitedHealthcare's quantity-limit denials for belatacept typically arise when the number of infusions, vials, or units billed in a given period exceeds the quantity the plan's policy anticipates for the approved dosing schedule. This can happen when a patient's clinical situation requires a dosing adjustment that the standard policy template does not automatically accommodate.

## Why This Denial Is Appealable

Quantity limits are set based on population-level assumptions. When an individual patient's clinical circumstances — transplant vintage, body size, rejection history, or physician-determined schedule — require a quantity outside that default, the prescriber can document the medical necessity of that quantity and request an exception. Quantity-limit denials are routinely overturned when the medical rationale is clearly documented.

## Federal Appeal Framework

• ACA §2719 external review: Binding IRO review is available after internal appeal is exhausted. File within approximately four months of denial — confirm the exact deadline on your EOB.
• ERISA §503: Employer-plan members can request the quantity-limit policy and clinical criteria the plan applied.
• Expedited review: Available when delay in receiving the correct quantity poses a genuine health risk — relevant for transplant patients where inadequate immunosuppression can lead to rejection.

## Concrete Appeal Steps

1. Obtain the denial letter specifying the quantity limit applied and the quantity billed. 2. Confirm the quantity your prescriber ordered is consistent with the FDA-approved prescribing label (obtain the label from FDA.gov or the manufacturer). 3. If the quantity reflects a label-consistent schedule, document that directly and appeal the limit as inconsistent with approved use. 4. If the quantity reflects an individualized clinical adjustment, have the prescriber document the specific clinical rationale. 5. Submit the internal appeal with documentation; escalate to external review if denied.

## Documentation to Gather

• FDA-approved prescribing label: confirm the dosing schedule applicable to your patient's situation and use it as the reference standard.
• Prescriber order and clinical rationale: letter explaining the prescribed quantity, its basis in the label and in the patient's clinical profile, and why reduction would compromise immunosuppressive coverage.
• Transplant records: current status, body weight documentation if relevant to dosing, and any notes on rejection risk.
• Infusion administration records: confirming prior infusions were administered as ordered and that the schedule is established.

## Criteria-Mapping Structure

Obtain UnitedHealthcare's quantity-limit policy for belatacept. Alongside each limit criterion, document the FDA label language that governs the applicable dosing scenario and the chart facts that support the prescribed quantity. This side-by-side mapping gives the IRO a clear path to reversing the denial without requiring any inference.